ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31)
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) of -$1.19 billion for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-24.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease · last filed 2012-02-24
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was -$1.35B.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was -$496.00M, a 163.76% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $178.90M.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-03-31 was $481.30M.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2011 was -$1.19B.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2010 was -$198.20M, a 162.94% decline from fiscal 2009.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2009 was $314.90M.
- ELI LILLY AND COMPANY other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2008 was -$2.80B, a 299.73% decline from fiscal 2007.
| Period end | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2011-12-31 | -$1.35B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | -$1.85B derived: sum of 2 quarters · filed 2012-02-24 | -$1.67B derived: sum of 3 quarters · filed 2012-02-24 | -$1.19B 10-K · filed 2012-02-24 |
| 2011-09-30 | -$496.00M 10-Q · filed 2011-10-28 | -$317.10M derived: sum of 2 quarters · filed 2011-10-28 | $164.20M 10-Q · filed 2011-10-28 | $23.90M derived: sum of 4 quarters · filed 2012-02-24 |
| 2011-06-30 | $178.90M 10-Q · filed 2011-07-29 | $660.20M 10-Q · filed 2011-07-29 | $519.90M derived: sum of 3 quarters · filed 2012-02-24 | $1.30B derived: sum of 4 quarters · filed 2012-02-24 |
| 2011-03-31 | $481.30M 10-Q · filed 2011-04-29 | $341.00M derived: sum of 2 quarters · filed 2012-02-24 | $1.12B derived: sum of 3 quarters · filed 2012-02-24 | $588.20M derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-12-31 | -$140.30M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | $637.60M derived: sum of 2 quarters · filed 2012-02-24 | $106.90M derived: sum of 3 quarters · filed 2012-02-24 | -$198.20M 10-K · filed 2012-02-24 |
| 2010-09-30 | $777.90M 10-Q · filed 2011-10-28 | $247.20M derived: sum of 2 quarters · filed 2011-10-28 | -$57.90M 10-Q · filed 2011-10-28 | -$354.30M derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-06-30 | -$530.70M 10-Q · filed 2011-07-29 | -$835.70M 10-Q · filed 2011-07-29 | -$1.13B derived: sum of 3 quarters · filed 2012-02-24 | -$840.80M derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-03-31 | -$305.00M 10-Q · filed 2011-04-29 | -$601.50M derived: sum of 2 quarters · filed 2012-02-24 | -$310.10M derived: sum of 3 quarters · filed 2012-02-24 | $353.40M derived: sum of 4 quarters · filed 2012-02-24 |
| 2009-12-31 | -$296.50M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | -$5.10M derived: sum of 2 quarters · filed 2012-02-24 | $658.40M derived: sum of 3 quarters · filed 2012-02-24 | $314.90M 10-K · filed 2012-02-24 |
| 2009-09-30 | $291.40M 10-Q · filed 2010-10-29 | $954.90M derived: sum of 2 quarters · filed 2010-10-29 | $611.40M 10-Q · filed 2010-10-29 | -$1.78B derived: sum of 4 quarters · filed 2011-02-22 |
| 2009-06-30 | $663.50M 10-Q/A · filed 2010-08-02 | $320.00M 10-Q/A · filed 2010-08-02 | -$2.07B derived: sum of 3 quarters · filed 2011-02-22 | -$2.68B derived: sum of 4 quarters · filed 2011-02-22 |
| 2009-03-31 | -$343.50M 10-Q · filed 2010-07-30 | -$2.73B derived: sum of 2 quarters · filed 2011-02-22 | -$3.34B derived: sum of 3 quarters · filed 2011-02-22 | -$3.34B derived: sum of 4 quarters · filed 2011-02-22 |
| 2008-12-31 | -$2.39B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-22 | -$3.00B derived: sum of 2 quarters · filed 2011-02-22 | -$2.99B derived: sum of 3 quarters · filed 2011-02-22 | -$2.80B 10-K · filed 2011-02-22 |
| 2008-09-30 | -$610.00M 10-Q · filed 2009-10-30 | -$602.90M derived: sum of 2 quarters · filed 2009-10-30 | -$409.10M 10-Q · filed 2009-10-30 | |
| 2008-06-30 | $7.10M 10-Q · filed 2009-07-31 | $200.90M 10-Q · filed 2009-07-31 | ||
| 2007-12-31 | $1.40B 10-K · filed 2010-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |